Zdrowie i gospodarka · 20/07/2015
FDA Releases Revised Draft Guidance for Lubiprostone Capsules
The FDA has made available a revised draft guidance for industry on lubiprostone capsules, providing specific recommendations for bioequivalence studies to support ANDA submissions.
Source: Federal Register — Food and Drug AdministrationOpen original release →